Clinical Trials Logo

Influenza A Virus, H7N9 Subtype clinical trials

View clinical trials related to Influenza A Virus, H7N9 Subtype.

Filter by:
  • None
  • Page 1

NCT ID: NCT02957656 Completed - Clinical trials for Influenza A Virus, H7N9 Subtype

Safety and Immunogenicity of Priming With Live Attenuated A/H7N9 Influenza Virus Vaccine Followed By Inactivated A/H7N9 Influenza Virus Vaccine With AS03 Adjuvant

Start date: December 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and immunogenicity of one dose of H7N9 pandemic live attenuated influenza vaccine (H7N9 pLAIV) followed by AS03-adjuvanted H7N9 pandemic inactivated influenza vaccine (H7N9 pIIV).

NCT ID: NCT02274545 Completed - Clinical trials for Influenza A Virus, H7N9 Subtype

Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old

Start date: October 2014
Phase: Phase 1
Study type: Interventional

H7N9 viruses have caused an outbreak of severe respiratory disease in 2013-2014 in China that affected many older adults. This study will evaluate the safety of and immune response to a live attenuated H7N9 vaccine in adults 50 to 70 years old.

NCT ID: NCT02151344 Completed - Clinical trials for Influenza A Virus, H7N9 Subtype

Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

Start date: May 2014
Phase: Phase 1
Study type: Interventional

H7N9 viruses have caused a recent outbreak of severe illness in humans in China. The purpose of this study is to evaluate the safety and immune response of an H7N9 A/Anhui/13 ca influenza virus vaccine followed by an inactivated subvirion H7N9 vaccine at varying intervals.

NCT ID: NCT01995695 Completed - Clinical trials for Influenza A Virus, H7N9 Subtype

Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults

Start date: October 2013
Phase: Phase 1
Study type: Interventional

H7N9 avian influenza (AI) viruses have caused a recent outbreak of severe respiratory disease in humans in China. The purpose of this study is to evaluate the safety and immunogenicity of a live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine in healthy adults. A single dose of inactivated subvirion H7N9 influenza vaccine will be administered 3 months later.